IPN60300

PreclinicalBiologic

Ipsen

IPN60300 is one of 3 biologic programs targeting Locally Advanced Solid Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Solid TumorRecruiting

Locally Advanced Solid TumorPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Locally Advanced Solid Tumor

#DrugCompanyPhaseTrials

Disitamab Vedotin

Pfizer

Phase 1

1 2

VC004

JJiangsu vcare pharmaceutical technology co., LTD

Phase 3

1 3

IPN60300

Ipsen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Locally Advanced Solid Tumor

NCT07213817

Clinical

Trials by Indication[1]

Locally Advanced Solid Tumor1 trial

An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumours.

Recruiting· Ipsen logo

Ipsen·Preclinical·NCT07213817·114 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IPN60300. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IPN60300 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IPN60300. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Ipsen

IPN60300

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Locally Advanced Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News